Theriva Biologics, Inc. Restructuring and Related Cost, Number of Positions Eliminated
Theriva Biologics, Inc. (TOVX) reported Restructuring and Related Cost, Number of Positions Eliminated of 7 employee for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated · last filed 2026-08-11
- Theriva Biologics, Inc. restructuring and related cost, number of positions eliminated for the quarter ending 2026-03-31 was 7.00 employee.
| Period end | Restructuring and Related Cost, Number of Positions Eliminated 3 month | Restructuring and Related Cost, Number of Positions Eliminated 6 month | Restructuring and Related Cost, Number of Positions Eliminated 9 month |
|---|---|---|---|
| 2026-06-30 | 7.00 employee 10-Q · filed 2026-08-11 | ||
| 2026-03-31 | 7.00 employee 10-Q · filed 2026-05-05 | ||
| 2025-09-30 | 7.00 employee 10-K · filed 2026-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |